With four late-stage assets, three FDA Breakthrough Therapy Designations, and two upcoming PDUFA decisions, Praxis Precision Medicines (PRAX), a CNS precision neuroscience biopharmaceutical company, is entering a defining chapter.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.